C110P.LA: Tanezumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant

Catalog No.: C110P.LA | **Product Name:** Tanezumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant

Tanezumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant. The research grade tanezumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C110P.LA
Product Name	Tanezumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Nerve Growth Factor
Summary	Recombinant Humanized IgG2 Monoclonal Antibody.
Isotype	LALAPG Fc Silent Mutant
Source/Host	The anti-human NGF monoclonal antibody tanezumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade tanezumab biosimilar specifically binds to the NGF protein.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by tanezumab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Tanezumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade tanezumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is tanezumab biosimilar research grade? Tanezumab is a humanized monoclonal antibody against nerve growth factor (NGF) designed as a treatment for pain via a novel mechanism distinct from conventional analgesics. Elevated NGF levels are associated with injury, inflammation, and chronic pain states. Tanezumab selectively binds to and inhibits NGF.

Tanezumab acts peripherally and has not shown a risk of addiction or misuse. The L234A, L235A, and P329G (LALAPG) triple mutation completely abolishes binding to Fc gamma receptors and complement protein C1q, providing a fully Fc-silent variant that allows researchers to analyze target-specific binding to NGF without non-specific effector cell activation.